Subsidiary Company of HUABAO INTL(00336) intends to adopt Huabao Flavours & Fragrances 2025 Restricted Stock Incentive Plan.
Huabao International (00336) announced that its main subsidiary, Huabao Flavors Co., Ltd., plans to adopt Huabao Group's 20% stake...
HUABAO INTL (00336) announced that its main subsidiary, Huabao Flavours & Fragrances Limited, plans to adopt the Huabao Flavours & Fragrances 2025 Restricted Stock Incentive Plan.
The purpose of the stock incentive plan is to further develop and improve the long-term incentive mechanism of Huabao Flavours & Fragrances, attract and retain outstanding talents, and fully motivate the directors, senior management, core management, technical and business personnel of Huabao Flavours & Fragrances, as well as other personnel deemed necessary to be incentivized by the board of directors of Huabao Flavours & Fragrances (the aforementioned personnel are directors or employees of Huabao Flavours & Fragrances and/or its subsidiary companies). The stock incentive plan aims to effectively align the interests of Huabao Flavours & Fragrances shareholders, Huabao Flavours & Fragrances, and its core team, focusing on the long-term development of Huabao Flavours & Fragrances, and fully protecting the interests of its shareholders.
 Related Articles 

On November 4th, IVD MEDICAL (01931) spent 10.31 million Hong Kong dollars to repurchase 1.823 million shares.

TWINTEK (06182) changes ownership, receives a discount of approximately 74.3% for the complete takeover offer, and is scheduled to resume trading on November 5th.

Pfizer Inc. (PFE.US) reported better-than-expected Q3 results and once again raised its full-year profit guidance, aiming to acquire the weight-loss drug company Metsera.
On November 4th, IVD MEDICAL (01931) spent 10.31 million Hong Kong dollars to repurchase 1.823 million shares.

TWINTEK (06182) changes ownership, receives a discount of approximately 74.3% for the complete takeover offer, and is scheduled to resume trading on November 5th.

Pfizer Inc. (PFE.US) reported better-than-expected Q3 results and once again raised its full-year profit guidance, aiming to acquire the weight-loss drug company Metsera.

RECOMMEND

World’s largest oil company Aramco posts higher Q3 net profit after lifting output
04/11/2025

HSBC, General Atlantic CEOs flag AI capex-revenue mismatch, ‘irrational exuberance’
04/11/2025

Pfizer Files Second Lawsuit Against Novo Nordisk and Metsera Amid Intensifying Bidding Battle Over Obesity Biotech
04/11/2025


